Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy

Therapeutic Drug Monitoring

Volumn 19, Issue 2, 1997, Pages 153-159

  Sundqvist, Anders ^a   Tomson, Torbjörn ^b   Lundkvist, Birgitta ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epilepsy; Monotherapy; Pharmacokinetics; Valproic acid

Indexed keywords

VALPROIC ACID;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MONITORING; ENTERIC COATED TABLET; FEMALE; HUMAN; MALE; MYOCLONUS EPILEPSY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031468894     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199704000-00006     Document Type: Article

References (19)

1. Bourgeois B. Valproic acid, clinical use. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995:633-9.
2. Chadwick DW. Concentration-effect relationships of valproic acid. Clin Pharmacokinet 1985;10:155-63.
3. Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JWA. The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 1979;20:61-8.
4. Loiseau P, Cenraud B, Levy RH, et al. Diurnal variations in steady state plasma concentrations of valproic acid in epileptic patients. Clin Pharmacokinet 1982;7:544-52.
5. Herngren L, Nergårdh A. Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. J Neurol 1988;235:491-5.
6. Sundqvist A. Juvenile myoclonic epilepsy: events before diagnosis. J Epilepsy 1990;3:189-92.
7. Ståhle L, Alm C, Ekqvist B, Lundkvist B, Tomson T. Monitoring free extracellular valproic acid by microdialysis in epileptic patients. Ther Drug Monit 1996;18:14-18.
8. Perucca E, Gatti G, Frigo GM, Crema A. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol 1978;5:313-8.
9. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Williams & Wilkins, 1995.
10. Bowdle TA, Patel IH, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980;28:486-92.
11. Gram L, Flachs H, Würtz-Jorgensen A, Parnas J, Andersen B. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979;20:303-12.
12. Gugler R, Eichelbaum M, Schell A, et al. The disposition of valproic acid. In: Johannesen SI, Morselli PL, Pippenger CE, Richens A, Schmidt D, Meinardi H, eds. Antiepileptic therapy: advances in drug monitoring. New York: Raven Press, 1980: 121-6.
13. Levy RH, Shen DS. Valproic acid, absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 605-19.
14. Hoffman F, von Unruh GE, Jancik BC. Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. Eur J Clin Pharmacol 1981;19:383-5.
15. Eadie MJ, Heazlewood V, McKauge L, Tyrer JH. Steady-state valproate pharmacokinetics during long term therapy. Clin Exp Neurol 1983;19:183-91.
16. Bauer LA, Davis R, Wilensky A, Raisys V, Levy RH. Diurnal variation in valproic acid clearance. Clin Pharmacol Ther 1984;35:505-9.
17. Davis SS, Hardy JG, Fara J. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986;27:886-92.
18. Leppik IE. Variability of phenytoin, carbamazepine and valproate concentrations in a clinic population. Epilepsy Res Suppl 1988;1:85-90.
19. Leppik IE. Compliance during treatment of epilepsy. Epilepsia 1988;29:S79-84.